Cyclosporine News and Research

RSS

Cyclosporine is a drug used to help reduce the risk of rejection of organ and bone marrow transplants by the body. It is also used in clinical trials to make cancer cells more sensitive to anticancer drugs.

CHOP experts identify new autoimmune disorder along with personalized treatment for young patient

Elijah Patino is a happy, healthy seven-year-old now, but it took a while to get there. For much of his life, he had a mysterious disease that made it painful to eat and painful to play.

2 Aug 2018

Aurinia’s Phase 2 trial evaluates voclosporin ophthalmic solution for treating dry eye syndrome

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the global immunology market, today announced the initiation of its Phase 2 trial evaluating voclosporin ophthalmic solution (VOS) for the treatment of dry eye syndrome (DES).

12 Jul 2018

Researchers uncover racial differences in debilitating itchy skin condition

An international team led by Johns Hopkins Medicine researchers has conducted what is believed to be the largest detailed published study of people with a poorly understood skin condition known as prurigo nodularis.

14 Jun 2018

FDA approves first oral medication for adults with moderately to severely active ulcerative colitis

The U.S. Food and Drug Administration today expanded the approval of Xeljanz (tofacitinib) to include adults with moderately to severely active ulcerative colitis. Xeljanz is the first oral medication approved for chronic use in this indication.

30 May 2018

Herbal products may affect properties of prescription drugs and lead to dangerous side effects

An analysis of published studies and reports indicates that a number of herbal products may affect the properties of prescription drugs, leading to alterations in the drugs' effectiveness as well as potentially dangerous side effects.

25 Jan 2018

Component of fire ant venom shows promise as a psoriasis treatment

In a new study involving laboratory mice, researchers have found that solenopsin and similar compounds could be beneficial for psoriasis.

11 Sep 2017

Immune booster could improve effectiveness of vaccines and cancer immunotherapy

Vaccines and cancer immunotherapies do essentially the same thing: They boost a person's immune system, better enabling it to fight an offender, be it microbe or malignancy.

29 Aug 2017

Penn State dermatologist clarifies common myths about psoriasis

Psoriasis is a much-misunderstood disease, often kept under wraps by sufferers who want to hide their skin lesions.

26 Aug 2016

Psoriasis treatments may help improve cardiovascular symptoms by reducing skin inflammation

Approximately 7.5 million people in the United States have psoriasis, and the impact of this disease goes far beyond its visible effects on the skin.

28 Jul 2016

Breakthrough technique removes potentially harmful additives from common injectable drugs

Bring the drugs, hold the suds. That summarizes a promising new drug-making technique designed to reduce serious allergic reactions and other side effects from anti-cancer medicine, testosterone and other drugs that are administered with a needle.

20 May 2016

Many kidney transplant patients may benefit from lower-than-standard dose of CNIs

The kidney is the most commonly transplanted organ in the United States, with more than 17,000 transplants performed each year. Following kidney transplant, patients are routinely placed on a regimen of immunosuppressant medications to prevent organ rejection, which often includes calcineurin inhibitors (CNIs) as the backbone medication of this regimen.

16 Mar 2016

Allo-HSCT Non-Relapse Related Mortality Reduction Revealed

A reduction in the risks of infection- and organ failure-related death has driven an improvement in non-relapse mortality among recipients of allogeneic haematopoietic stem cell transplantation, Japanese research suggests.

17 Feb 2016

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).

17 Nov 2015

Study suggests combination of MMF and CNIs can protect against rare lymphoma

16 Oct 2015

Researchers link organ transplant drug to rise in rare lymphoma

A study led by Johns Hopkins researchers has linked the immunosuppressive drug mycophenolate mofetil (MMF) to an increased risk of central nervous system (CNS) lymphoma in solid organ transplant patients. But the same study also found that another class of immunosuppressive drugs, called calcineurin inhibitors (CNIs), given alone or in combination with MMF, appears to protect transplant patients against this rare form of lymphoma.

15 Oct 2015

Immune submits Bertilimumab IND application to FDA for treatment of Bullous Pemphigoid

Immune Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug Application in the U.S. to expand recruiting for its first in class lead product candidate, Bertilimumab, for the treatment of Bullous Pemphigoid (BP).

7 Oct 2015

Immune Pharmaceuticals’ CEO establishes stock trading plan

Immune Pharmaceuticals, Inc. announced today that its Chief Executive Officer, Dr. Daniel Teper, has established a stock trading plan with respect to the purchases of up to an aggregate of $250,000 of shares of Immune common stock in accordance with Rule 10b5-1 under the Exchange Act and other applicable federal securities laws and regulations adopted by the Securities and Exchange Commission.

16 Sep 2015

Cyclosporine drug does not improve outcomes in STEMI patients receiving PCI

The immunosuppressant drug cyclosporine did not improve clinical outcomes compared to placebo in patients receiving percutaneous coronary intervention (PCI) for the more severe form of heart attack known as ST-segment elevation myocardial infarction (STEMI).

31 Aug 2015

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy.

26 Aug 2015

ESC Congress to highlight results from global trials in six press conferences

Members of the press will be the first to hear the highly anticipated results from global trials in six press conferences devoted to hot lines research.

13 Aug 2015